Teva Pharmaceutical Industries Limited (TEVA) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
17.65
↓-27% vs avg
5yr avg: 24.11
30Y Low9.9·High52.5
P/FCF
↓
36.52
↑+45% vs avg
5yr avg: 25.27
30Y Low7.3·High125.1
P/B Ratio
↑
5.34
↑+115% vs avg
5yr avg: 2.48
30Y Low0.7·High8.3
ROE
↑
20.7%
↓+438% vs avg
5yr avg: -6.1%
30Y Low-61%·High27%
Debt/EBITDA
↓
5.50
↓-56% vs avg
5yr avg: 12.46
30Y Low1.1·High23.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TEVA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Teva Pharmaceutical Industries Limited trades at 30.0x earnings, 27% above its 5-year average of 23.5x, sitting at the 59th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 34%. On a free-cash-flow basis, the stock trades at 36.5x P/FCF, 45% above the 5-year average of 25.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $41.9B | $36.6B | $24.9B | $11.7B | $10.1B | $8.9B | $10.6B | $10.7B | $15.7B | $19.3B | $34.8B |
| Enterprise Value | $55.8B | $50.4B | $39.7B | $28.6B | $28.9B | $30.2B | $34.8B | $36.1B | $42.9B | $50.8B | $69.6B |
| P/E Ratio → | 30.01 | 26.01 | — | — | — | 21.08 | — | — | — | — | 517.86 |
| P/S Ratio | 2.43 | 2.12 | 1.51 | 0.74 | 0.68 | 0.56 | 0.63 | 0.63 | 0.84 | 0.86 | 1.59 |
| P/B Ratio | 5.34 | 4.63 | 4.36 | 1.44 | 1.18 | 0.79 | 0.96 | 0.71 | 1.00 | 1.03 | 1.00 |
| P/FCF | 36.52 | 31.89 | 33.28 | 13.87 | 9.72 | 37.57 | 16.56 | 25.52 | 8.77 | 7.31 | 8.06 |
| P/OCF | 25.43 | 22.20 | 19.99 | 8.54 | 6.37 | 11.11 | 8.69 | 19.87 | 6.44 | 5.49 | 6.67 |
P/E links to full P/E history page with 30-year chart
TEVA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Teva Pharmaceutical Industries Limited's enterprise value stands at 17.6x EBITDA, 27% below its 5-year average of 24.1x. The Healthcare sector median is 14.4x, placing the stock at a 23% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.92 | 2.40 | 1.81 | 1.94 | 1.90 | 2.09 | 2.14 | 2.27 | 2.27 | 3.18 |
| EV / EBITDA | 17.65 | 15.97 | 52.52 | 18.04 | — | 9.90 | — | 28.19 | 209.16 | — | 19.09 |
| EV / EBIT | 25.85 | 23.58 | 11.78 | 70.64 | — | 9.80 | 11.39 | 13.28 | — | — | 50.76 |
| EV / FCF | — | 43.93 | 53.01 | 33.98 | 27.72 | 127.80 | 54.53 | 86.06 | 23.89 | 19.28 | 16.11 |
TEVA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Teva Pharmaceutical Industries Limited earns an operating margin of 12.5%. Operating margins have expanded from 2.7% to 12.5% over the past 3 years, signaling improving operational efficiency. ROE of 20.7% indicates solid capital efficiency. ROIC of 7.7% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.8% | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% | 46.4% | 44.6% | 44.0% | 48.4% | 54.1% |
| Operating Margin | 12.5% | 12.5% | -1.8% | 2.7% | -14.7% | 10.8% | -21.4% | -2.6% | -8.7% | -78.1% | 9.8% |
| Net Profit Margin | 8.2% | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | -24.0% | -5.9% | -11.4% | -72.7% | 1.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.7% | 20.7% | -23.7% | -6.7% | -24.7% | 3.7% | -30.5% | -6.5% | -12.4% | -60.5% | 1.0% |
| ROA | 3.5% | 3.5% | -4.0% | -1.3% | -5.3% | 0.8% | -7.4% | -1.7% | -3.3% | -19.9% | 0.4% |
| ROIC | 7.7% | 7.7% | -1.0% | 1.2% | -5.5% | 3.8% | -7.1% | -0.8% | -2.6% | -21.8% | 3.1% |
| ROCE | 8.0% | 8.0% | -1.0% | 1.4% | -6.4% | 4.6% | -8.8% | -1.0% | -3.3% | -27.5% | 3.7% |
TEVA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Teva Pharmaceutical Industries Limited carries a Debt/EBITDA ratio of 5.5x, which is highly leveraged (67% above the sector average of 3.3x). Net debt stands at $13.8B ($17.4B total debt minus $3.6B cash). Interest coverage of just 2.3x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.20 | 2.20 | 3.16 | 2.48 | 2.51 | 2.09 | 2.39 | 1.82 | 1.83 | 1.73 | 1.02 |
| Debt / EBITDA | 5.50 | 5.50 | 23.91 | 12.71 | — | 7.70 | — | 21.38 | 141.05 | — | 9.81 |
| Net Debt / Equity | — | 1.75 | 2.58 | 2.08 | 2.18 | 1.89 | 2.19 | 1.68 | 1.72 | 1.68 | 0.99 |
| Net Debt / EBITDA | 4.38 | 4.38 | 19.55 | 10.67 | — | 6.99 | — | 19.83 | 132.36 | — | 9.54 |
| Debt / FCF | — | 12.04 | 19.73 | 20.10 | 18.00 | 90.23 | 37.96 | 60.54 | 15.12 | 11.97 | 8.05 |
| Interest Coverage | 2.34 | 2.34 | 3.58 | 0.39 | -2.40 | 3.46 | 4.05 | 2.84 | -1.88 | -19.66 | 1.03 |
TEVA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.04x means Teva Pharmaceutical Industries Limited can comfortably meet its short-term obligations, though there is limited excess liquidity.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 0.98 | 1.02 | 1.05 | 1.14 | 0.99 | 0.98 | 0.96 | 0.86 | 0.92 |
| Quick Ratio | 0.80 | 0.80 | 0.75 | 0.69 | 0.72 | 0.79 | 0.65 | 0.66 | 0.63 | 0.58 | 0.65 |
| Cash Ratio | 0.26 | 0.26 | 0.26 | 0.26 | 0.24 | 0.20 | 0.17 | 0.14 | 0.12 | 0.05 | 0.05 |
| Asset Turnover | — | 0.42 | 0.42 | 0.36 | 0.34 | 0.33 | 0.33 | 0.29 | 0.31 | 0.32 | 0.24 |
| Inventory Turnover | 2.62 | 2.62 | 2.82 | 2.04 | 2.07 | 2.17 | 2.03 | 2.11 | 2.23 | 2.35 | 2.03 |
| Days Sales Outstanding | — | 78.45 | 67.49 | 78.51 | 90.39 | 104.11 | 100.37 | 122.68 | 112.71 | 116.23 | 125.37 |
TEVA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Teva Pharmaceutical Industries Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 3.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.5% | 0.1% | 4.7% | 3.7% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | 396.0% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.3% | 3.8% | — | — | — | 4.7% | — | — | — | — | 0.2% |
| FCF Yield | 2.7% | 3.1% | 3.0% | 7.2% | 10.3% | 2.7% | 6.0% | 3.9% | 11.4% | 13.7% | 12.4% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.1% | 4.7% | 3.7% |
| Shares Outstanding | — | $1.2B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.0B | $1.0B | $961M |
Peer Comparison
Compare TEVA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TEVAYou | $42B | 30.0 | 17.6 | 36.5 | 51.8% | 12.5% | 20.7% | 7.7% | 5.5 |
 VTRS | $20B | -5.8 | 248.5 | 10.5 | 35.1% | -18.6% | -21.1% | -6.6% | 108.7 |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 AMRX | $4B | 62.4 | — | 16.0 | 36.9% | -0.2% | 15.7% | -0.2% | — |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 MCK | $92B | 29.2 | 18.7 | 17.6 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 CAH | $44B | 28.7 | 16.0 | 23.6 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 CVS | $111B | 62.8 | 13.1 | 14.3 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full TEVA Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See TEVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TEVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TEVA vs VTRS
Side-by-side business, growth, and profitability comparison vs Viatris Inc..
Start ComparisonTEVA — Frequently Asked Questions
Quick answers to the most common questions about buying TEVA stock.
What is Teva Pharmaceutical Industries Limited's P/E ratio?
Teva Pharmaceutical Industries Limited's current P/E ratio is 30.0x. The historical average is 31.3x. This places it at the 59th percentile of its historical range.
What is Teva Pharmaceutical Industries Limited's EV/EBITDA?
Teva Pharmaceutical Industries Limited's current EV/EBITDA is 17.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.0x.
What is Teva Pharmaceutical Industries Limited's ROE?
Teva Pharmaceutical Industries Limited's return on equity (ROE) is 20.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 4.6%.
Is TEVA stock overvalued?
Based on historical data, Teva Pharmaceutical Industries Limited is trading at a P/E of 30.0x. This is at the 59th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Teva Pharmaceutical Industries Limited's profit margins?
Teva Pharmaceutical Industries Limited has 51.8% gross margin and 12.5% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited's Debt/EBITDA ratio is 5.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.